Related Experiment Video
Updated: Aug 24, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Use of pharmacogenetics to guide warfarin therapy
Deepak Voora1, Howard L McLeod, Charles Eby
1Departments of Medicine and Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Abstract:
The Human Genome Project heralds new opportunities for pharmacogenetics, the use of genetics to individualize the application of pharmaceuticals in the practice of medicine (1-3). Single nucleotide polymorphisms (SNPs) and other genetic variants in genes responsible for absorption, metabolism and excretion have been associated with alterations in drug disposition or effect. Warfarin is a potential target for pharmacogenetics-based dosing because of its wide use, variability in individual response, high prevalence of genetic variants and severity of adverse drug reactions (4). The genotype assays for genetic variants relevant to warfarin are widely used and are being developed for commercial use (5), making the promise of a pharmacogenetics-based approach a near reality.
Related Concept Videos
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Principles of Pharmacogenetics: Types of Genetic Variants